ADC Therapeutics SA financials
$1.23−2.38%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19.2M | $20.9M | $23.1M | $16.4M | $18.8M | $23.0M | $16.9M | $18.5M | $17.4M | $18.1M | $16.8M | $14.5M |
| Gross profit | $16.9M | $17.2M | $21.4M | $15.2M | $18.0M | $21.0M | $15.5M | $17.6M | $16.2M | $15.5M | $15.6M | $14.3M |
| Gross margin | 87.8% | 82.7% | 92.6% | 92.7% | 95.6% | 91.1% | 91.9% | 95.4% | 93.0% | 86.1% | 92.8% | 98.6% |
| Operating income | -$25.4M | -$25.2M | -$17.9M | -$31.0M | -$44.1M | -$28.5M | -$32.4M | -$35.6M | -$29.0M | -$33.6M | -$40.0M | -$36.1M |
| Net income | -$16.6M | -$33.0M | -$6.4M | -$41.0M | -$56.6M | -$38.6M | -$30.7M | -$44.0M | -$36.5M | -$46.6M | -$85.0M | -$46.7M |
| Net margin | −86.1% | −158.1% | −27.8% | −249.4% | −300.7% | −167.6% | −181.7% | −238.1% | −209.9% | −258.2% | −506.4% | −322.4% |
| Diluted EPS | $-0.11 | $-0.21 | $-0.04 | $-0.30 | $-0.50 | $-0.36 | $-0.29 | $-0.42 | $-0.38 | $-0.56 | $-1.03 | $-0.57 |
| EBITDA | -$22.7M | -$25.2M | -$18.3M | -$30.6M | -$31.1M | -$28.5M | -$32.1M | -$35.2M | -$28.7M | -$33.3M | -$39.6M | -$35.8M |
| Operating cash flow | -$11.8M | -$29.7M | -$31.1M | -$29.6M | -$24.1M | -$56.3M | -$21.9M | -$25.0M | -$32.8M | -$44.1M | -$31.6M | -$36.7M |
| Free cash flow | -$11.8M | -$29.7M | -$31.1M | -$29.6M | -$24.1M | -$56.6M | -$21.9M | -$25.3M | -$32.9M | -$44.6M | -$32.0M | -$37.3M |
| Diluted shares | 155.0M | 154.1M | 150.9M | 136.4M | 113.7M | 107.2M | 105.6M | 104.8M | 95.7M | 82.6M | 82.3M | 82.3M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $219.1M | $231.0M | $261.3M | $234.7M | $264.6M | $194.7M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $116.6M | $115.7M | $115.5M | $115.2M | $114.5M | $113.8M |
| Total assets | $279.4M | $291.5M | $323.1M | $289.8M | $321.6M | $272.5M |
| Total liabilities | $507.6M | $507.9M | $509.0M | $527.9M | $520.7M | $510.8M |
| Shareholders' equity | -$228.2M | -$216.4M | -$185.8M | -$238.2M | -$199.2M | -$238.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology